{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:18:20Z","timestamp":1792459100126,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>TAFRO syndrome is a systemic inflammatory disorder that manifests as thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Renal dysfunction is frequently complicated with TAFRO syndrome, however, it is challenging to perform kidney biopsy in patients with TAFRO syndrome in the presence of thrombocytopenia. Renal histology in TAFRO syndrome mainly shows membranoproliferative glomerulonephritis (MPGN)-like lesions or thrombotic microangiopathy (TMA)-like glomerulopathy. We review our case and previous reports of TAFRO syndrome with kidney biopsy findings and discuss the renal pathophysiology of TAFRO syndrome.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We describe a previously healthy 48- year-old woman with TAFRO syndrome. Kidney biopsy performed before the treatment showed diffuse global endocapillary proliferative changes with endothelial cell swelling, double contours of partial capillary walls, and mesangiolysis, consistent with TMA-like glomerulopathy. Glucocorticoid therapy including steroid pulse was ineffective and she developed anasarca, renal dysfunction and oliguria. Hemodialysis was required. However, the anti-Interleukin (IL)-6 receptor antibody (tocilizumab) therapy was very effective. An increase in urinary volume was achieved about 2 weeks after the tocilizumab therapy and hemodialysis was discontinued. To investigate the renal pathophysiology of TAFRO syndrome, we performed immunohistological staining of vascular endothelial growth factor (VEGF)-A, CD34, and D2\u201340, in our case and a normal control kidney. Glomerular VEGF-A was especially positive in podocytes both, in the control and in the case, with no significant difference and there was a significant increase of VEGF-A staining area in the cortical peritubular capillaries in the case. Both glomerular and renal cortical CD34 expression were significantly decreased in our case. D2\u201340 expression in cortex was not significantly different.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We reviewed our case and other 10 previous reports about renal biopsy findings in TAFRO syndrome and found that glomerular microangiopathy was a common finding. IL-6-VEGF-axis-induced glomerular microangiopathy may play a crucial role in developing acute kidney injury in TAFRO syndrome and the anti-IL-6 receptor antibody therapy may be useful for TAFRO syndrome refractory to glucocorticoids. About the pathophysiology of VEGF in TAFRO syndrome, VEGF balance in the glomerulus and perhaps in the peritubular capillary system as well may be critical. Further investigation is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-019-1574-9","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T14:59:24Z","timestamp":1571324364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3236-9078","authenticated-orcid":false,"given":"Yoshikuni","family":"Nagayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoka","family":"Yagame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nariyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"issue":"1","key":"1574_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3960\/jslrt.53.57","volume":"53","author":"H Kawabata","year":"2013","unstructured":"Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June,2012) and Nagoya meetings (22 September,2012). J Clin Exp Hematop. 2013;53(1):57\u201361 doi: 10.3960\/jslrt.53.57.","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"1574_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","volume":"103","author":"Y Masaki","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103(6):686\u201392. \n                    https:\/\/doi.org\/10.1007\/s12185-016-1979-1\n                    \n                  .","journal-title":"Int J Hematol"},{"issue":"2","key":"1574_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24242","volume":"91","author":"N Iwaki","year":"2016","unstructured":"Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220\u20136. \n                    https:\/\/doi.org\/10.1002\/ajh.24242\n                    \n                  .","journal-title":"Am J Hematol"},{"issue":"6","key":"1574_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3109\/14397595.2015.1059982","volume":"27","author":"M Kawashima","year":"2017","unstructured":"Kawashima M, Usui T, Okada H, et al. TAFRO syndrome: 2 cases and review of the literature. Mod Rheumatol. 2017;27(6):1093\u20137. \n                    https:\/\/doi.org\/10.3109\/14397595.2015.1059982\n                    \n                  .","journal-title":"Mod Rheumatol"},{"issue":"24","key":"1574_CR5","doi-asserted-by":"publisher","first-page":"e11057","DOI":"10.1097\/MD.0000000000011057","volume":"97","author":"Y Furuto","year":"2018","unstructured":"Furuto Y, Hashimoto H, Horiuti H, Shibuya Y. Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor.: A case report. Medicine (Baltimore). 2018;97(24):e11057 doi: 10.1097%2FMD.0000000000011057.","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"1574_CR6","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2169\/internalmedicine.0806-18","volume":"57","author":"S Ito","year":"2018","unstructured":"Ito S, Uchida T, Itai H, et al. Serial manifestation of acute kidney injury and nephrotic syndrome in a patient with TAFRO syndrome. Intern Med. 2018;57(21):3129\u201333. \n                    https:\/\/doi.org\/10.2169\/internalmedicine.0806-18\n                    \n                  .","journal-title":"Intern Med"},{"issue":"1","key":"1574_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5414\/CNCS109400","volume":"6","author":"Y Noda","year":"2018","unstructured":"Noda Y, Saka Y, Kato A, Mimura T, Naruse T. Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin Nehrol Case Stud. 2018;6(1):16\u201320 doi: 10.5414%2FCNCS109400.","journal-title":"Clin Nehrol Case Stud"},{"issue":"40","key":"1574_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008216","volume":"96","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Medicine (Baltimore). 2017;96(40):e8216 doi: 10.1097%2FMD.0000000000008216.","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"1574_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006271","volume":"96","author":"FF Jose","year":"2017","unstructured":"Jose FF, Kerbauy LN, Perini GF, et al. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Medicine (Baltimore). 2017;96(13):e6271 doi: 10.1097%2FMD.0000000000006271.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1574_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s13730-018-0319-0","volume":"7","author":"S Noda-Narita","year":"2018","unstructured":"Noda-Narita S, Sumida K, Sekine A, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7(1):162\u20138 doi: 10.1007%2Fs13730-018-0319-0.","journal-title":"CEN Case Rep"},{"issue":"2","key":"1574_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s13730-018-0338-x","volume":"7","author":"T Ozeki","year":"2018","unstructured":"Ozeki T, Tsuji M, Yamamoto J, Shigematsu C, Maruyama S. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep. 2018;7(2):243\u20137. \n                    https:\/\/doi.org\/10.1007\/s13730-018-0338-x\n                    \n                  .","journal-title":"CEN Case Rep."},{"key":"1574_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.humpath.2018.03.021","volume":"82","author":"H Mizuno","year":"2018","unstructured":"Mizuno H, Sekine A, Oguro M, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;82:258\u201363. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2018.03.021\n                    \n                  .","journal-title":"Hum Pathol"},{"issue":"8","key":"1574_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2169\/internalmedicine.9556-17","volume":"57","author":"A Nakamori","year":"2018","unstructured":"Nakamori A, Akagaki F, Yamaguchi Y, Arima R, Sugiura T. Nephrotic syndrome with thrombocytopenia, lymphadenopathy, systemic inflammation, and splenomegaly. Intern Med. 2018;57(8):1123\u20139 doi: 10.2169%2Finternalmedicine.9556-17.","journal-title":"Intern Med"},{"issue":"6","key":"1574_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1574_CR15","doi-asserted-by":"publisher","first-page":"e1.1","DOI":"10.1053\/j.ajkd.2003.09.023","volume":"43","author":"A Seida","year":"2004","unstructured":"Seida A, Wada J, Morita Y, et al. Multicentric Castleman\u2019s disease associated with glomerular microangiopathy and MPGN-like lesions: does vascular endothelial cell-derived growth factor play causative or protective roles in injury? Am J Kidney Dis. 2004;43(1):e1.1\u20137. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2003.09.023\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1574_CR16","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1046\/j.1523-1755.2000.00422.x","volume":"58","author":"YG Kim","year":"2000","unstructured":"Kim YG, Suga S, Kang DH, et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int. 2000;58(6):2390\u20139. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00422.x\n                    \n                  .","journal-title":"Kidney Int"},{"issue":"4","key":"1574_CR17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1046\/j.1523-1755.2001.00935.x","volume":"60","author":"A Suga","year":"2001","unstructured":"Suga A, Kim YG, Joly A, et al. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int. 2001;60(4):1297\u2013308. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00935.x\n                    \n                  .","journal-title":"Kidney Int"},{"issue":"11","key":"1574_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336 doi: 10.1056%2FNEJMoa0707330.","journal-title":"N Engl J Med"},{"issue":"10","key":"1574_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1681\/ASN.2010030295","volume":"21","author":"K Sison","year":"2010","unstructured":"Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010;21(10):1691\u2013701 doi: 10.1681%2FASN.2010030295.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1574_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/ndt\/gfq427","volume":"26","author":"K El Karoui","year":"2011","unstructured":"El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26(2):599\u2013609. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfq427\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"key":"1574_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.humpath.2015.10.013","volume":"49","author":"T Kusano","year":"2016","unstructured":"Kusano T, Takano H, Kang D, et al. Endothelial cell injury in acute and chronic glomerular lesions in patients with IgA nephropathy. Hum Pathol. 2016;49:135\u201344. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2015.10.013\n                    \n                  .","journal-title":"Hum Pathol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1574-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1574-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1574-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T23:22:11Z","timestamp":1602804131000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1574-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1574-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable for this case report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}